# NCT03680521 (NCT03680521)

> Neoadjuvant Sitravatinib in Combination With Nivolumab in Patients With Clear Cell Renal Cell Carcinoma

No report yet. It can be ordered.

- Drugs tested: sitravatinib plus nivolumab
- Indication: locally advanced clear cell renal cell carcinoma

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03680521
- Phase: PHASE2
- Status: COMPLETED
- Sponsor: Mirati Therapeutics Inc.
- Conditions: Clear Cell Renal Cell Carcinoma
- Interventions: Sitravatinib; Nivolumab
- Enrollment: 25
- Primary outcome: Percentage of Participants Who Achieved a Point in Time Objective Response (Either Complete or Partial Response [CR or PR]) Prior to Surgery
- Primary outcome: Point in Time Objective Response Prior to Surgery

## Indexed commentary on NCT03680521 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 5 posts on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=nct03680521